Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Operations: 2019-2025

Historic Cash from Operations for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$31.2 million.

  • C4 Therapeutics' Cash from Operations fell 29.31% to -$31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.5 million, marking a year-over-year decrease of 32.63%. This contributed to the annual value of -$65.2 million for FY2024, which is 39.01% up from last year.
  • As of Q3 2025, C4 Therapeutics' Cash from Operations stood at -$31.2 million, which was down 158.83% from -$12.1 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Cash from Operations peaked at -$5.0 million during Q2 2024, and registered a low of -$33.3 million during Q1 2025.
  • For the 3-year period, C4 Therapeutics' Cash from Operations averaged around -$22.6 million, with its median value being -$24.0 million (2023).
  • As far as peak fluctuations go, C4 Therapeutics' Cash from Operations surged by 73.82% in 2024, and later plummeted by 142.40% in 2025.
  • Over the past 5 years, C4 Therapeutics' Cash from Operations (Quarterly) stood at -$25.7 million in 2021, then fell by 13.47% to -$29.1 million in 2022, then increased by 17.57% to -$24.0 million in 2023, then increased by 25.31% to -$17.9 million in 2024, then decreased by 29.31% to -$31.2 million in 2025.
  • Its Cash from Operations stands at -$31.2 million for Q3 2025, versus -$12.1 million for Q2 2025 and -$33.3 million for Q1 2025.